Biological application of PAMAM dendrimer nanodevices in vitro and in vivo

Dendrimer-Based Nanomedicine

Volumn , Issue , 2008, Pages 175-207

  Thomas, Thommey P ^a   Kukowska Latallo, Jolanta F ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855769674     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.4032/9789814241182     Document Type: Chapter

References (55)

1. Y. Luo and G. D. Prestwich, Cancer-targeted polymeric drugs, Current Cancer Drug Targets, 2(3), 209-226, 2002.
2. D. G. Savage and K. H., Imatinib mesylate- a new oral targeted therapy, [see comment], New England Journal of Medicine, 346(9), 683-693, 2002.
3. I. J. Majoros, T. P. Thomas, and J. R. Baker Jr., Molecular engineering in nanotechnology: Engineered drug delivery. In, M. Rieth, W. Schommers, (Eds.), Handbook of Theoretical and Computational Nanotechnology, American Scientific Publishers, 2006.
4. R. Duncan and R. Duncan, The dawning era of polymer therapeutics, Nature Reviews Drug Discovery, 2(5), 347-360, 2003.
5. L.Y. Qiu and Y. H. Bae, Polymer architecture and drug delivery, Pharmaceutical Research, 23(1), 1-30, 2006.
6. M. J. and R. Duncan, Polymer conjugates: Nanosized medicines for treating cancer, Trends in Biotechnology, 24(1), 39-47, 2006.
7. A. Nori and J. Kopecek, Intracellular targeting of polymer-bound drugs for cancer chemotherapy, Advanced Drug Delivery Reviews, 57(4), 609-636, 2005.
8. A. K. Patri, I. J. Majoros, and J. R. Baker Jr., Dendritic polymer macro-molecular carriers for drug delivery, Current Opinion in Chemical Biology, 6(4), 466-471, 2002.
9. S. Svenson and D.A. Tomalia, Dendrimers in biomedical applicationsreflections on the field, Advanced Drug Delivery Reviews, 57(15), 2106-2129, 2005.
10. H. F. Chow, T. K. Mong, M. F. Nongrum, and C. W. Wan, The synthesis and properties of novel functional dendritic molecules, Tetrahedron, 54, 8534-8660, 1998.
11. M. Fischer and F.̈gtle, Dendrimers. From design to appplication- A progress report, Angew. Chem. Int. Ed. Engl., 38, 884-905, 1999.
12. D. A. Tomalia and I. J. Majoros, Dendrimeric supramolecular and supramacro-molecular assemblies, In, A. Ciferri, Ed. Supramolecular Polymers, Marcel Dekker, NY, 359-435, 2002.
13. U. Boas and P. M. H. Heegaard, Dendrimers in drug research, Chemical Society Reviews, 33(1), 43-63, 2004.
14. A. W. Bosman, H. M. Janssen, and E. W. Meijer, About dendrimers: Structure, physical properties, and applications, Chem. Rev., 99, 1665-1668, 1999.
15. A. Quintana, E. Raczka, L. Piehler, I. Lee, A. Myc, I. Majoros, A. K. Patri, T. Thomas, J. Mule, and J. R. Baker Jr., Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor, Pharmaceutical Research, 19(9), 1310-1316, 2002.
16. J. F. Kukowska-Latallo, K. A. Candido, Z. Cao, S. S. Nigavekar, I. J. Majoros, T. P. Thomas, L. P. Balogh, M. K. Khan, and J. R. Baker Jr., Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer, Cancer Research, 65(12), 5317-5324, 2005.
17. I. J. Majoros, B. Keszler, S. Woehler, T. Bull, and J. R. Baker Jr., Acetylation of poly(amidoamine) dendrimers, Macromolecules, 36, 5526-5529, 2003.
18. I. J. Majoros, T. P. Thomas, C. B. Mehta, and J. R. Baker Jr., Poly(amidoamine) dendrimer-based multifunctional engineered nanodevice for cancer therapy, Journal of Medicinal Chemistry, 48(19), 5892-5899, 2005.
19. T. P. Thomas, I. J. Majoros, A. Kotlyar, J. F. Kukowska-Latallo, A. Bielinska, A. Myc, and J. R. Baker Jr., Targeting and inhibition of cell growth by an engineered dendritic nanodevice, Journal of Medicinal Chemistry, 48(11), 3729-3735, 2005.
20. T. P. Thomas, M. T. Myaing, J. Y. Ye, K. Candido, A. Kotlyar, J. Beals, P. Cao, B. Keszler, A. K. Patri, T. B. Norris, and J. R. Baker Jr., Detection and analysis of tumor fluorescence using a two-photon optical fiber probe, Biophysical Journal, 86(6), 3959-3965, 2004.
21. T. P. Thomas, J. Y. Ye, C.-S. Yang, M. Myaing, I. J. Majoros, A. Kotlyar, Z. Cao, T. B. Norris, and J. R. Baker Jr., Tissue distribution and real-time fluorescence measurement of a tumor-targeted nanodevice by a two photon optical fiber fluorescence probe, Proceedings of the SPIE, 6095, 2006.
22. H. Kobayashi, S. Kawamoto, T. Saga, N. Sato, A. Hiraga, T. Ishimori, J. Konishi, K. Togashi, and M.W. Brechbiel, Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macro-molecularMR contrast agents, Magnetic Resonance in Medicine, 46(4), 781-788, 2001.
23. R. Duncan and L. Izzo, Dendrimer biocompatibility and toxicity, Advanced Drug Delivery Reviews, 57(15), 2215-2237, 2005.
24. R. Jevprasesphant, J. Penny, R. Jalal, D. Attwood, N. B. McKeown, and A. D'Emanuele, The influence of surface modification on the cytotoxicity of PAMAM dendrimers, International Journal of Pharmaceutics, 252(1-2), 263-266, 2003.
25. N. Malik, R. Wiwattanapatapee, R. Klopsch, K. Lorenz, H. Frey, J. W. Weener, E. W. Meijer, W. Paulus, and R. Duncan, Dendrimers: Relationship between structure and biocompatibility in vitro, and preliminary studies on the biodist-ribution of 125I-labelled polyamidoamine dendrimers in vivo, [erratum appears in J. Control Release 2000 Aug. 10, 68(2), 299-302]. Journal of Controlled Release, 65(1-2), 133-148, 2000.
26. S. Hong, A. U. Bielinska, A. Mecke, B. Keszler, J. L. Beals, X. Shi, L. Balogh, B. G. Orr, J. R. Baker Jr., and M. M. Banaszak Holl, Interaction of poly(amido-amine) dendrimers with supported lipid bilayers and cells: Hole formation and the relation to transport, Bioconjugate Chemistry, 15(4), 774-82, 2004.
27. J. C. Roberts, M. K. Bhalgat, R. T. Zera, J. C. Roberts, M. K. Bhalgat, and R. T. Zera, Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers, Journal of Biomedical Materials Research, 30(1), 53-65, 1996.
28. H. Kobayashi and M.W. Brechbiel, Nano-sized MRI contrast agents with dendrimer cores, Advanced Drug Delivery Reviews, 57(15), 2271-2286, 2005.
29. S. D. Konda, M. Aref, S. Wang, M. Brechbiel, and E. C. Wiener, Specific targeting of folate-dendrimer MRI contrast agents to the high affinity folate receptor expressed in ovarian tumor xenografts, Magma, 12(2-3), 104-113, 2001.
30. R. Shukla, T. P. Thomas, J. Peters, A. Kotlyar, A. Myc, and J. R. Baker Jr., Tumor angiogenic vasculature targeting with PAMAM dendrimer-RGD conjugates, Chem. Commun. (Camb.), 46, 5739-5741, 2005.
31. T. P. Thomas, A. K. Patri, A. Myc, M. T. Myaing, J. Yong Ye, T. B. Norris, and J. R. Baker Jr., In vitro targeting of synthesized antibody- conjugated dendrimer nanoparticles, Biomacromolecules, 5(6), 2269-2274, 2004.
32. L. Balogh and D. A. Tomalia, Poly (amidoamine) dendrimer-templated nanocomposites, 1: Synthesis of zerovalent copper nanoclusters, J. Am. Chem. Soc., 120, 7355-7356, 1998.
33. N. Beck Tan, L. Balogh, and S. Trevino, Structure of metallo-organic nano-composites produced from dendrimer complexes, Proceedings of ACS PMSE, 77, 120, 1997.
34. A. D'Emanuele and D. Attwood, Dendrimer-drug interactions, Advanced Drug Delivery Reviews, 57(15), 2147-2162, 2005.
35. L. P. Balogh, D. R. Swanson, D. A. Tomalia, G. L. Hagnauer, and A. T. McManus, Dendrimer-silver complexes and nanocomposites as antimicrobial agents, Nano Letters, 1, 18-21, 2001.
36. A. Bielinska, J. D. Eichman, I. Lee, J. R. Baker Jr., and L. P. Balogh, Imaging {Au0-PAMAM} gold-dendrimer nanocomposites in cell, J. Nanoparticle Res., 4, 395-403, 2002.
37. N. Malik, E. G. Evagorou, R. Duncan, N. Malik, E. G. Evagorou, and R. Duncan, Dendrimer-platinate: A novel approach to cancer chemotherapy, Anti-Cancer Drugs, 10(8), 767-776, 1999.
38. A. K. Patri, J. F. Kukowska-Latallo, and J. R. Baker Jr., Targeted drug delivery with dendrimers: Comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex, Advanced Drug Delivery Reviews, 57(15), 2203-2214, 2005.
39. A. R. Hilgenbrink and P. S. Low, Folate receptor-mediated drug targeting: From therapeutics to diagnostics, Journal of Pharmaceutical Sciences, 94(10), 2135-2146, 2005.
40. N. Parker, M. J. Turk, E. Westrick, J. D. Lewis, P. S. Low, and C. P. Leamon, Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay, Analytical Biochemistry, 338(2), 284-293, 2005.
41. Y. Lu and P. S. Low, Folate-mediated delivery of macromolecular anticancer therapeutic agents, Advanced Drug Delivery Reviews, 54(5), 675-693, 2002.
42. W. Arap, R. Pasqualini, and E. Ruoslahti, Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model, [see comment], Science, 279(5349), 377-380, 1998.
43. R. Murali, Q. Liu, X. Cheng, A. Berezov, M. Richter, K. Furuchi, M. I. Greene, and H. Zhang, Antibody like peptidomimetics as large scale immunodetection probes, Cellular & Molecular Biology, 49(2), 209-216, 2003.
44. M. Shadidi and M. Sioud, Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells, FASEB Journal, 17(2), 256-258, 2003.
45. S. S. Dharap, B. Qiu, G. C. Williams, P. Sinko, S. Stein, and T. Minko, Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides, Journal of Controlled Release, 91(1-2), 61-73, 2003.
46. D. Schrama, R. A. Reisfeld, and J. C. Becker, Antibody targeted drugs as cancer therapeutics, Nature Reviews Drug Discovery, 5(2), 147-159, 2006.
47. A. K. Patri, A. Myc, J. Beals, T. P. Thomas, N. H. Bander, and J. R. Baker Jr., Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy, Bioconjugate Chemistry, 15(6), 1174-1181, 2004.
48. R. Shukla, T. P. Thomas, J. L. Peters, J. Kukowska-Latallo, A. K. Patri, A. Kotlyar, and J. R. Baker Jr., HER2 specific tumor targeting with dendrimer conjugated anti-HER2 mAb, Bioconjugate Chemistry, 17, 1109-1115, 2006.
49. M. S. Dennis, H. K. Jin, D. Dugger, R. H. Yang, L. McFarland, A. Ogasawara, S. Williams, M. J. Cole, S. Ross, and R. Schwall, Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent, Cancer Research, 67(1), 254-261, 2007.
50. I. J. Majoros, A. Myc, T. Thomas, C. B. Mehta, and J. R. Baker Jr., PAMAM dendrimer-based multifunctional conjugate for cancer therapy: Synthesis, characterization, and functionality, Biomacromolecules, 7(2), 572-579, 2006.
51. R. Krishna and L. D. Mayer, Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs, Eur. J. Pharm. Sci., 11(4), 265-283, 2000.
52. J. C. Roberts, M. K. Bhalgat, and R. T. Zera, Preliminary biological evaluation of polyamidoamine (PAMAM) Starburst dendrimers, J. Biomed. Mater. Res., 30(1), 53-65, 1996.
53. S. S. Nigavekar, L. Y. Sung, M. Llanes, A. El-Jawahri, T. S. Lawrence, C. W. Becker, L. Balogh, and M. K. Khan, 3H dendrimer nanoparticle organ/tumor distribution, Pharm. Res., 21(3), 476-483, 2004.
54. D. R. Green and G. Kroemer, Pharmacological manipulation of cell death: Clinical applications in sight? Journal of Clinical Investigation, 115(10), 2610-2617, 2005.
55. Y. Choi, T. Thomas, A. Kotlyar, M. T. Islam, and J. R. Baker Jr., Synthesis and functional evaluation of DNA-assembled polyamidoamine dendrimer clusters for cancer cell-specific targeting [see comment], Chemistry & Biology, 12(1), 35-43, 2005.